Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 3 Study of ASP015K - A Randomized, Double-blind, Placebo-controlled Confirmatory Study of the Safety and Efficacy of ASP015K in Patients With Rheumatoid Arthritis Who Had an Inadequate Response to DMARDs

NCT02308163 is registered in ClinicalTrials.gov with Astellas Pharma Inc as lead sponsor.

NCT NCT02308163
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02308163 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 3 Study of ASP015K - A Randomized, Double-blind, Placebo-controlled Confirmatory Study of the Safety and Efficacy of ASP015K in Patients With Rheumatoid Arthritis Who Had an Inadequate Response to DMARDs
Lead sponsor
Astellas Pharma Inc
Phase
Phase 3
Overall status
Completed
Start date
August 8, 2014
Completion date
November 22, 2017
Enrollment
509 (actual)
Sites
153

Conditions

As the registry lists them; a condition with its own page is linked.

rheumatoid arthritis